This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sesso, R. Articles by Ajzen, H. Search for Related Content PubMed PubMed Citation Articles by Sesso, R. Articles by Ajzen, H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOPHOSPHAMIDE METHYLPREDNISOLONE Social Bookmarking                   What's this?

A Controlled Trial of Pulse Cydophosphamide Versus Pulse Methylprednisolone in Severe Lupus Nephritis

Division of Nephrology, Department of Medicine, Escola Paulista de Medicine, Sao Paulo, Brazil

Marcia Monteiro

Division of Nephrology, Department of Medicine, Escola Paulista de Medicine, Sao Paulo, Brazil

Emilia Sato

Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Sao Paulo, Brazil

Gianna Kirsztajn

Division of Nephrology, Department of Medicine, Escola Paulista de Medicine, Sao Paulo, Brazil

Liana Silva

Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Sao Paulo, Brazil

Horacio Ajzen

Division of Nephrology, Department of Medicine, Escola Paulista de Medicine, Sao Paulo, Brazil

We carried out a prospective randomized trial comparing pulse cyclophosphamide and pulse methylprednisolone in 29 patients with severe lupus nephritis in activity. Patients were assigned to one of two regimens: monthly pulse cyclophosphamide (0.5-1.0 g/m ² body surface area) for 4 months, followed by bimonthly doses for 4 months and quarterly doses for 6 months (14 patients) or pulse methylprednisolone (10-20 mg/kg weight) initially for 3 consecutive days and thereafter in the same intervals as the alternative regimen (15 patients). The mean follow-up was 15 months. Two patients in the cyclophosphamide group and three in the methylprednisolone group died. Renal failure (doubling of serum creatinine) developed in four patients in the cyclophosphamide group compared with five patients in the methylprednisolone group. Cumulative probability of not doubling serum creatinine was similar for cyclophosphamide and methylprednisolone groups (0.66 vs 0.69, respectively, P > 0.20, after 18 months). Cumulative probability of survival without renal failure was also not significantly different (0.61 and 0.63, respectively, P > 0.20, after 18 months). These results suggest that pulse cyclophosphamide is as effective as pulse methylprednisolone in preserving renal function in patients with severe lupus nephritis.

Key Words: Systemic lupus erythematosus • Lupus nephritis • Cyclophosphamide • Methylprednisolone • Pulse • Treatment

Lupus, Vol. 3, No. 2, 107-112 (1994)
DOI: 10.1177/096120339400300209


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Mak, A. A. C. Cheak, J. Y. S. Tan, H. C. Su, R. C. M. Ho, and C. S. Lau Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression Rheumatology, June 3, 2009; (2009) kep120v1. [Abstract] [Full Text] [PDF]

				C C Mok, R W S Wong, and K N Lai Treatment of severe proliferative lupus nephritis: the current state Ann Rheum Dis, September 1, 2003; 62(9): 799 - 804. [Abstract] [Full Text] [PDF]

				D. Adu The evidence base for the treatment of lupus nephritis in the new millennium Nephrol. Dial. Transplant., August 1, 2001; 16(8): 1536 - 1538. [Full Text] [PDF]

				M Mosca, R Neri, S Giannessi, A Pasquariello, R Puccini, W Bencivelli, and S Bombardieri Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis Lupus, April 1, 2001; 10(4): 253 - 257. [Abstract] [PDF]

				K Takada, G G Illei, and D T Boumpas Cyclophosphamide for the treatment of systemic lupus erythematosus Lupus, March 1, 2001; 10(3): 154 - 161. [Abstract] [PDF]